Page 258 - 2020_02-Haematologica-web

J-C. Gris et al.
an inflammatory disease, whose treatment is based on drugs suspected to increase the risk of cancer (methotrex- ate, cyclophosphamide...), as it has been reported that can- cer rates are increased in patients with systemic lupus ery- thematosus. Only one of these women developed a cancer during the follow-up (HR 0.74; 95% CI: 0.10-5.54).
Standardized incidence ratios of cancer were calculated:
for the whole cohort (2.00; 95% CI: 1.49-2.62), the APS group (2.89; 95% CI: 1.89-4.23), the Thrombophilia group (1.60; 95% CI: 0.69-3.15) and the Control group (1.49; 95% CI: 0.89-2.37).
Focusing on the APS group, we studied the association between aPL antibodies and incident cancers, adjusted for the age of the women at inclusion. Initial positivity for LA
Figure 1. Flow diagram of patients in the NOH-APS cohort and its three groups. HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepa- titis C virus; aPL Ab: antiphospholipid antibody; APS: antiphospholipid syn- drome
492
haematologica | 2020; 105(2)